Skip to main content

Gen-Probe Licenses Tumor Cell Detection Technology from AdnaGen for Diagnostic Tests

NEW YORK, Jan. 4 (GenomeWeb News) -- Gen-Probe has licensed a tumor cell detection technology from AdnaGen of Germany, the San Diego-based company said this week.

 

The technology allows for the detection of rare, circulating tumor cells by first isolating cancerous cells from healthy cells using an immunoassay followed by measuring gene expression in these cells. 

 

Under the terms of the agreement, Gen-Probe obtains exclusive access to AdnaGen's technology for molecular diagnostic tests for prostate and bladder cancer. Gen-Probe will pay AdnaGen license fees of $1 million, as well as $750,000 in the first quarter of 2006 or when AdnaGen's patent issues, whichever happens later. Gen-Probe may also pay AdnaGen three milestones totaling an additional $2.25 million. In addition, AdnaGen will receive royalties on sales of products developed using its technology.

 

Gen-Probe also obtains options to exclusively license the technology for kidney, ovarian, and cervical cancer. Also, the company has a three-year right of first refusal for using the technology for breats, colon, and lung cacner tests.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.